Open AccessLumican promotes joint fibrosis through TGF‐β signaling
Author(s) -
Xiao Dahai,
Liang Tangzhao,
Zhuang Ze,
He Ronghan,
Ren Jianhua,
Jiang Shihai,
Zhu Lei,
Wang Kun,
Shi Dehai
Publication year - 2020
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12974
Subject(s) - lumican , myofibroblast , extracellular matrix , microbiology and biotechnology , synovial joint , fibroblast , proteoglycan , cartilage , joint contracture , medicine , fibrosis , cancer research , chemistry , pathology , biology , contracture , anatomy , osteoarthritis , in vitro , decorin , biochemistry , surgery , articular cartilage , alternative medicine
Proposed mechanisms for lumican in joint contracture include: (a) increased lumican with posttraumatic damage that has caused a transition from a normal joint capsule to joint contracture; and (b) stimulating synovial fibroblasts with recombinant lumican leads to increased transcription of alpha‐smooth muscle actin, matrix metallopeptidase 9, Collagen I, plasminogen activator inhibitor 1 and transforming growth factor‐β in vitro , possibly through the transforming growth factor‐β pathway. Thus, lumican may affect capsule fibrosis in joint contracture.